Cancer staging

Results: 459



#Item
21Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, January 18, Shionogi & Co., Ltd. (Head Office: Osaka; President

Shionogi Receives Approval of Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, January 18, Shionogi & Co., Ltd. (Head Office: Osaka; President

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:18
22®  BecomeAnEX.org Answers to frequently asked questions about CT scans to help inform a discussion with your doctor

® BecomeAnEX.org Answers to frequently asked questions about CT scans to help inform a discussion with your doctor

Add to Reading List

Source URL: www.michigancancer.org

Language: English - Date: 2014-10-14 15:24:29
23An innovative technology for in vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients and immunofluorescent detection of ALK protein  4th European Lung Cancer Conference (ELLC-4)

An innovative technology for in vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients and immunofluorescent detection of ALK protein 4th European Lung Cancer Conference (ELLC-4)

Add to Reading List

Source URL: www.gilupi.de

Language: English - Date: 2014-05-27 05:41:15
24Data Nuances – Tips in analyzing Collaborative Stage (CS) data with a focus on CS version 2 for data 2010+ (November 2012 and 2013 SEER data submissions)

Data Nuances – Tips in analyzing Collaborative Stage (CS) data with a focus on CS version 2 for data 2010+ (November 2012 and 2013 SEER data submissions)

Add to Reading List

Source URL: surveillance.cancer.gov

Language: English - Date: 2015-04-16 11:01:05
25Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines Osaka, Japan, March 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tes

Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines Osaka, Japan, March 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tes

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English
26Local S6 Leadership Connection Friday, July 26, OFFICER ELECTIONS Information and absentee ballot request forms for the October 23, 2013 Officers, Chief Stewards and Grievance Committee Election have been maile

Local S6 Leadership Connection Friday, July 26, OFFICER ELECTIONS Information and absentee ballot request forms for the October 23, 2013 Officers, Chief Stewards and Grievance Committee Election have been maile

Add to Reading List

Source URL: www.locals6.org

Language: English - Date: 2013-07-26 08:45:43
27NOT FOR IMMEDIATE RELEASE  SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i

NOT FOR IMMEDIATE RELEASE SHIONOGI & CO., LTD ANNOUNCES THAT NALDEMEDINE MEETS PRIMARY ENDPOINT IN A PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION FLORHAM PARK, NJ (March 30, 2015) – Naldemedine, an i

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2015-04-27 07:57:32
28Isolation of circulating tumor cells in vivo by the CellCollector™ technology 31. Deutscher Krebskongress Abstracttitel: ID 189 Berlin,

Isolation of circulating tumor cells in vivo by the CellCollector™ technology 31. Deutscher Krebskongress Abstracttitel: ID 189 Berlin,

Add to Reading List

Source URL: www.gilupi.de

Language: English - Date: 2014-06-30 05:59:57
29Microsoft Word - References & tool list for providers and pts

Microsoft Word - References & tool list for providers and pts

Add to Reading List

Source URL: www.michigancancer.org

Language: English - Date: 2014-10-14 15:24:29
30EBCC-9 GlasgowMarch 2014 Abstract No. 71 Poster Board No. 062 A novel technology for in vivo isolation of circulating tumor cells in breast cancer patients

EBCC-9 GlasgowMarch 2014 Abstract No. 71 Poster Board No. 062 A novel technology for in vivo isolation of circulating tumor cells in breast cancer patients

Add to Reading List

Source URL: www.gilupi.de

Language: English - Date: 2014-05-27 05:40:45